TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)

ANZUP TheraP team

Research output: Contribution to journal › Article › peer-review

125 Citations (Scopus)

Fingerprint

Dive into the research topics of 'TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science